Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2026
Early postoperative carbohydrate antigen 19-9 normalization drives prognosis after pancreatic ductal adenocarcinoma resection.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elemosho Abdulaziz, Chatzipanagiotou Odysseas P, Angez Meher, Baldo Andrea, Mevawalla Areesh, Alizai Qaidar, Pawlik Timothy M
Аннотация
BACKGROUND: The prognostic utility of carbohydrate antigen 19-9 (CA19-9) may vary based on clinical and gene[A1] tic factors, including FUT2/FUT3 mutations or UGT1A1 alleles. We sought to examine early postoperative changes in CA19-9 relative to prognosis after resection of pancreatic ductal adenocarcinoma (PDAC). [A1]AU: Please ensure that genes (not proteins) are italicized, per journal style.
METHODS: Patients undergoing resection of PDAC were identified from the All of Us Research Program. Patients were categorized into neoadjuvant therapy (NAT) followed by resection (NAT-to-resection) and surgery-first. The primary endpoint was real-world time-to-treatment failure (rwTTF). Genomic and sensitivity analyzes excluded post-treatment draws with total bilirubin levels >2 mg/dL and were restricted to CA19-9 producers.
RESULTS: Among 283 patients who underwent pancreatic resection, 48 underwent NAT-to-resection and 235 underwent surgery-first. Index years ranged between 1999 and 2023. Baseline CA19-9 distributions differed markedly by pathway. Patients in the NAT-to-resection group had a median pretreatment CA19-9 of 273 U/mL, whereas patients in the surgery-first group had a median pretreatment CA19-9 of 19 U/mL, with 68.7% of patients demonstrating normal values. Carcinoembryonic antigen (CEA) levels were available preoperatively in 88 patients and postoperatively in 41 patients; among phenotypic CA19-9 nonproducers, few individuals had an elevated CEA level. In CA19-9 trajectory analysis, median rwTTF was 1185.5 days with normal-to-normal values, 693 days for elevated-to-normalized, and 138 days for those with elevated-to-persistently-elevated values. After excluding planned adjuvant therapy from the rwTTF endpoint, higher pretreatment CA19-9 and greater postoperative CA19-9 change were independently associated with rwTTF, whereas binary postoperative normalization alone was not.
CONCLUSION: Basing a prognosis on a single CA19-9 value or percent drop may be insufficient, particularly because many surgery-first patients had normal baseline CA19-9 values. Perioperative CA19-9 trajectories provided a more clinically informative framework, with persistent postoperative elevation identifying the highest-risk group after PDAC resection.
METHODS: Patients undergoing resection of PDAC were identified from the All of Us Research Program. Patients were categorized into neoadjuvant therapy (NAT) followed by resection (NAT-to-resection) and surgery-first. The primary endpoint was real-world time-to-treatment failure (rwTTF). Genomic and sensitivity analyzes excluded post-treatment draws with total bilirubin levels >2 mg/dL and were restricted to CA19-9 producers.
RESULTS: Among 283 patients who underwent pancreatic resection, 48 underwent NAT-to-resection and 235 underwent surgery-first. Index years ranged between 1999 and 2023. Baseline CA19-9 distributions differed markedly by pathway. Patients in the NAT-to-resection group had a median pretreatment CA19-9 of 273 U/mL, whereas patients in the surgery-first group had a median pretreatment CA19-9 of 19 U/mL, with 68.7% of patients demonstrating normal values. Carcinoembryonic antigen (CEA) levels were available preoperatively in 88 patients and postoperatively in 41 patients; among phenotypic CA19-9 nonproducers, few individuals had an elevated CEA level. In CA19-9 trajectory analysis, median rwTTF was 1185.5 days with normal-to-normal values, 693 days for elevated-to-normalized, and 138 days for those with elevated-to-persistently-elevated values. After excluding planned adjuvant therapy from the rwTTF endpoint, higher pretreatment CA19-9 and greater postoperative CA19-9 change were independently associated with rwTTF, whereas binary postoperative normalization alone was not.
CONCLUSION: Basing a prognosis on a single CA19-9 value or percent drop may be insufficient, particularly because many surgery-first patients had normal baseline CA19-9 values. Perioperative CA19-9 trajectories provided a more clinically informative framework, with persistent postoperative elevation identifying the highest-risk group after PDAC resection.